Dr Thomas Newsom-Davis is a Consultant Medical Oncologist based at The Chelsea and Westminster Hospital NHS Foundation Trust.

Dr Newsom-Davis trained at University College and Middlesex School of Medicine, and graduated in anatomy and medicine in 1998. He subsequently specialised in medical oncology at Charing Cross and Hammersmith Hospitals. During this time he completed a PhD in tumour immunology, funded by Cancer Research UK, and went on to become a Clinical Lecturer in medical oncology at Imperial College London, supported by the Wellcome Trust and Academy of Medical Sciences. He has published several peer-reviewed papers and presented at many conferences.

Dr Newsom-Davis specialises in the treatment of lung cancer, mesothelioma and other thoracic malignancies. Dr Newsom-Davis has taught widely at both under-gradate and post-graduate levels, as well as being an invited lecturer for various organisations including the Royal College of Physicians and the British Medical Journal. He foundered the first Royal Society of Medicine/LCA acute oncology course, and also runs regular simulation based acute oncology training courses at Chelsea and Westminster. His work was recognised in the 2011 Health Services Journal Awards.

Awards Dr Newsom-Davis has received include: 2011 Health Services Journal Awards, Clinical Service Redesign (short listed), 2006 McElwain Scholarship, Association of Cancer Physicians, and in 2006 President’s Prize, Royal College of Physicians.

He is a member of the Royal College of Physicians, Association of Cancer Physicians, European Society of Medical Oncology, British Thoracic Oncology Group and the British Medical Association.

Dr Susan Cleator is a Consultant Clinical Oncologist based at Charing Cross Hospital, part of Imperial College Healthcare NHS Foundation Trust.

Dr Cleator trained at Oxford University and Hospitals, and undertook her oncology training at the Charing Cross, Hammersmith, Mount Vernon and The Royal Marsden Hospitals. During this period she also spent three years working full-time on her PhD project at the Institute of Cancer Research and Royal Marsden Hospital. This focused on identifying a molecular assay for predicting the response of breast cancers to chemotherapy. She has published on this and a number of other aspects of oncology.

She works closely with her surgical colleagues at St Mary's hospital where she is responsible for the chemotherapy and radiotherapy aspects of their treatment, specializing in breast, colorectal and lymphomatous cancers. 

Dr Cleator was previously a member of Breast Cancer Studies Group (overseeing Breast Cancer National Research portfolio) and is a member of the American Association Cancer Physicians and the British Medical Association.

Professor Stephen Devereux is a Consultant Haematologist based at King's College Hospital in London.  He is also Professor in Lymphoma Biology at King's College London.

Professor Devereus trained in Haematology at the Royal Free and University College London Hospitals where he also worked as a Senior Lecturer.

Professor Devereux has extensive experience in the diagnosis and treatment of blood cancers with a particular interest in lymphoid malignances and chronic lymphatic leukaemia. He plays an active role in both laboratory and clinical research and directs an internationally competitive team working on the biology of lymphoma at King's College London.

Professor Devereux is Clinical Director of the London South Comprehensive Local Research Network and the South East London Cancer Research Network. He is a medical advisor to the Lymphoma Association and serves on the executive of the UK-CLL forum executive, the NCRN CLL subgroup and the Leukaemia and Lymphoma Research Fund Clinical Trials Committee.

Professor SM Lee is a Professor of Medical Oncology at UCL Cancer Institute and Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and a Consultant Oncologist at UCLH.

Prof Lee studied medicine at St Mary’s Hospital Medical School, University of London, before completing his medical oncology fellowship training at Guy’s and Christie Hospitals. He was a recipient of the American Association for Cancer Research Upjohn Award in 1993, McElwain Prize by the Association of Cancer Physicians in 1994, and completed his postgraduate PhD degree at CRUK Manchester Paterson Institute in 1994. He was appointed a Consultant Medical Oncologist at UCLH in 1998 to specialize in the treatment lung cancer and lymphoma.

Dr Simon Chowdhury is a Consultant Medical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.

Dr Chowdhury was appointed to Guy’s hospital in 2007 to lead the medical oncology group in the treatment of urological cancers.

Dr Chowdhury received his first degree from the University of Cambridge and qualified as a doctor at Guys and St Thomas’ Medical School. He completed his PhD in tumour targeting at University College London. He also trained at St George’s and The Royal Marsden Hospitals. He was a Visiting Fellow at the Dana Farber Cancer Institute in Boston, with which he retains strong links. Between 2000 and 2003. Dr Chowdhury was a Research Fellow for Cancer Research UK.

He is actively involved in clinical trial research into urological cancer, and is a member of the London Kidney Cancer Group which aims to develop further clinical trials in the London area. He is the joint lead for the treatment of urological cancers within the South East London Cancer Network.

He has co-authored over 20 papers in peer-reviewed journals and contributed chapters to six medical texts

Dr Ronald Beaney is a Consultant Clinical Oncologist based at Guys and St. Thomas' NHS Trust in London.

Dr Beaney did his undergraduate training in Scotland followed by posts abroad and in the UK. His oncology training was at the Hammersmith Hospital in London where his MD thesis was on the role of positron emission topography in oncology.

He has been a Consultant Clinical Oncologist attached to Guy's and St Thomas' and King's College Hospitals in London. His major clinical interests lie in tumours of the brain (gliomas) and pelvis (prostate and gynaecological tumours). His current interests are novel drugs for treating tumours and the use of stereotactic radiation, both gamma knife and cyber knife.

Dr Beaney has been on the Faculty Board of the Royal College of Radiologists and an examiner for the same college. He is a Council member of the British neuro-oncology society and a member of the brain tumour working party of the European Organisation for the treatment of Cancer (EORTC) and he is a member of several UK, European and American Cancer Societies and examiner for the Royal College of Radiologists.

Dr Rebecca Kristeleit is Clinical Senior Lecturer and Consultant Medical Oncologist at University College London and University College London Hospitals NHS Foundation Trust.

Dr Kristeleit specialises in the treatment of gynaecological cancers.

Dr Kristeleit qualified in medicine from St Andrew’s and Manchester Universities including eight months at the University of Lausanne (Switzerland) on an Erasmus scholarship. Following general medical training in London, Rebecca undertook her medical oncology training at The Royal Marsden Hospital and a CRUK-funded research fellowship at the Institute of Cancer Research. Subsequently, Rebecca spent a year as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital gaining specialist experience in the design and conduct of early phase clinical trials and translational medicine.

She also has a specialist interest in drug development as well and is leading several clinical trials of novel agents relevant to gynecological malignancies including PARP inhibitors.

Professor Paul Ellis is Professor of Cancer Medicine based at King’s College London and Consultant Medical Oncologist at Guy’s & St Thomas’ Hospital.

Prof Ellis has responsibility for the management of breast cancer.

He studied medicine at Otago University in New Zealand before completing his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital in London. He took up his present post in 1997 and has held a number of senior management roles since then including Head of Medical Oncology at Guy’s & St Thomas’, Medical Director for the South East London Cancer Network (SELCN) and Head of Breast Cancer Clinical Research for Guy’s & St Thomas’ and the KCL Division of Cancer Medicine.

He is the author of over 100 peer reviewed scientific papers in the breast cancer field, and has been on the Editorial Board of a number of Oncology Journals including Journal of Clinical Oncology. His major breast cancer research interests include novel clinical research strategies in the adjuvant and neoadjuvant setting with an emphasis on the integration of novel therapies. He was involved in chairing the UK Dept of Health Advisory committee on the introduction of Herceptin into UK clinical practice, and co-authouring the national guidelines on Herceptin use.

Professor Ellis was the principal investigator and co-chair of the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including being Co-PI on the MARIANNE and KAMILLA trials. He continues to take an active leadership role within the UK and European Clinical Trials community.

Over the last 5 years he has been actively involved in the development and growth of the Sarah Cannon Research Centre in London. He has taken a leadership role in the breast programme and links closely with Sarah Cannon in Nashville and the other centres in the US.

Dr Mark Harries is a Consultant Medical Oncologist based at Guy’s & St Thomas’ Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine.

Dr Harries specialises in the treatment of Breast Cancer and Melanoma.

Mark graduated from Cambridge University and underwent clinical training at The Royal London Hospital. He trained in Medical Oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College London.

Dr Harries is a member of the Association of Cancer Physicians, Royal College of Physicians, American Society of Clinical Oncology, European Society of Medical Oncology and the British Medical Association.

Dr Lucy Brazil is a Consultant Clinical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.

Dr Brazl has a special interest in neuro-oncology, in particular, the treatment of glioblastoma multiforme and low grade glioma (including oligodendroglioma). She trained in oncology at Royal Marsden Hospital and Guy's and St Thomas’ Hospitals. She was awarded an MD in 2007 for research into breast cancer genetics at the Institue of Cancer Research and Breakthrough Breast Cancer. 

Dr Brazil is an active member of The National Cancer Institute Brain Tumour Clinical Studies Group, as well as The European Organisation for Research and Treatment of Cancer Brain Tumour Group. She is also Chairman of The Brain Tumour Palliative Care / Quality of Life subgroup.

Dr Brazil was Chief investigator for the CODEL brain tumour study using chemotherapy and radiotherapy for Gliomas,

Chairman of the brain tumour Palliative care QOL sub-group, and Systemic Chemotherapy Neuro-oncology Research lead at Guy’s and St Thomas’.